key: cord-0855739-zje5unr0
authors: Hines, Adam M.; Murphy, Neal; Mullin, Christine; Barillas, Julia; Barrientos, Jacqueline C.
title: Henoch-Schönlein Purpura Presenting Post COVID-19 Vaccination
date: 2021-06-30
journal: Vaccine
DOI: 10.1016/j.vaccine.2021.06.079
sha: 415fdff6e8bf24fc83a4f584b5403de63aad8a07
doc_id: 855739
cord_uid: zje5unr0

nan

There was no funding provided for this manuscript. COI: JCB receives research funding from AstraZeneca, Oncternal, TG therapeutics, Pharmacyclics/Abbvie, honoraria from Janssen, and has worked as a consultant for AstraZeneca, Pharmacyclics/Abbvie, Beigene, Genentech, Gilead, Innate. .

To the Editor:

Henoch-Schönlein purpura (HSP) is a systemic vasculitic syndrome mostly observed in children. Herein, we present the case of a 40-year-old female with history of occasional headaches and Hashimoto's thyroiditis (euthyroid not on medication) who presented for evaluation of a new purpuric rash on her gluteal region of unknown duration ( Figure 1) . The patient reported a severe headache the day before.

Twenty days prior to presentation, she received the second dose of the Pfizer-BioNTech BNT16B2b2 mRNA vaccine, reporting mild fatigue and myalgias lasting 2 days post injection. Fourteen days prior to presentation, she had intrauterine insemination (IUI) preceded by choriogonadotropin alfa injection 2 days prior and letrozole a week prior, a regimen she had received previously without complications.

Physical exam was otherwise unremarkable. Laboratory results revealed a mild leukocytosis of 12.98 K/uL (neutrophil predominant). Platelet count, coagulation profile, fibrinogen, haptoglobin, quantitative immunoglobulins (Ig) including IgA/G/M, electrolytes, kidney and liver function, kappa and lambda free light chains, and urine protein level were all within normal levels. The urinalysis showed 2 red blood cells per high power field. Pregnancy test was negative. Rheumatology, hematology, and fertility doctors agreed the rash was consistent with early-stage HSP triggered by Pfizer-BioNTech BNT16B2b2 mRNA vaccination. Given lack of systemic involvement, she was asked to monitor symptoms. Rash resolved within a week.

HSP is a diagnosis of exclusion without specific diagnostic tests. While HSP is the most common form of primary childhood vasculitis in Europe and North America, it is significantly less common in adults (3-14 cases per million). 1 Clinical presentation is variable and, in addition to purpuric lesions, additional organ involvement and associated complications can be observed. 2 The etiology of HSP is not well understood and seems to be a combination of genetic, environmental, and infectious causes. HSP has previously been reported following immunization with various vaccines, mostly within 12 weeks post vaccination. 3 The aim of this report is to highlight a possible association between COVID-19 vaccination (Pfizer-BioNTech BNT16B2b2 mRNA vaccine) and first onset of HSP in a previously well adult. There were no cases reported amongst 43,448 participants in the Pfizer-BioNTech BNT16B2b2 mRNA vaccine trial. 4 Although confounding, the hormonal exposure for IUI was brief and without prior history of side effects. She denied recent infections or exposure to SARS-CoVID-2. Skin lesions with features of vasculitis have been reported in COVID-19 infections ranging from asymptomatic to fatal. 5 Given the appearance and typical distribution of the rash, the dermatology team felt that a skin biopsy was not necessary for the diagnosis of HSP. Although the mRNA vaccine field developed extremely rapid with two mRNA vaccines under Emergency Use Authorization, the platform is safe and lacks the potential risk of infection or insertional mutagenesis. To our knowledge, this is the first case of HSP after the administration of a COVID mRNA vaccine which was likely the cause. Given the temporal association, this vaccine has the potential to induce post-vaccination vasculitis, a rare adverse event. As mass vaccination campaigns start worldwide, particularly of younger patients where HSP is more frequently observed, physicians should be aware of this complication, but should continue to encourage vaccination efforts given the well documented safety profile and efficacy of the Pfizer-BioNTech BNT16B2b2 mRNA vaccine. 

Epidemiology of the vasculitides. Semin Respir Crit Care Med

Childhood Vasculitis. Front Pediatr

Spontaneous reports of vasculitis as an adverse event following immunization: A descriptive analysis across three international databases. Vaccine

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

COVID-19 vasculitis and novel vasculitis mimics

There has been no significant financial support for this work that could have influenced its outcome.COI Disclosure for the corresponding author as follows: JCB receives research funding from AstraZeneca, Oncternal, TG therapeutics, Pharmacyclics/Abbvie, honoraria from Janssen, and has worked as a consultant for AstraZeneca, Pharmacyclics/Abbvie, Beigene, Genentech, Gilead, Innate.There are no other COI noted for the other authors listed.We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us.We confirm that we have given due consideration to the protection of intellectual property associated with this work and that there are no impediments to publication, including the timing of publication, with respect to intellectual property. In so doing we confirm that we have followed the regulations of our institutions concerning intellectual property.We understand that the Corresponding Author is the sole contact for the Editorial process (including Editorial Manager and direct communications with the office). She is responsible for communicating with the other authors about progress, submissions of revisions and final approval of proofs. We confirm that we have provided a current, correct email address which is accessible by the Corresponding Author. Signed by all authors as follows: